{"id":398451,"date":"2020-12-11T16:18:05","date_gmt":"2020-12-11T21:18:05","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398451"},"modified":"2020-12-11T16:18:05","modified_gmt":"2020-12-11T21:18:05","slug":"arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/","title":{"rendered":"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2013 Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET \u2013<\/em>\n      <\/p>\n<p align=\"left\">NEW HAVEN, Conn., Dec.  11, 2020  (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that\u00a0it will host a live webcast presentation on Monday, December 14, 2020 at 8:00 a.m. ET to provide clinical program updates for its PROTAC\u00ae protein degraders ARV-471 and ARV-110. The presentation will include updates from the Phase 1 dose escalation studies of ARV-471 in patients with locally advanced or metastatic ER positive \/ HER2 negative breast cancer and ARV-110 in men with metastatic castrate-resistant prostate cancer. The event will also include an overview of the recently initiated Phase 2 dose expansion study for ARV-110.<\/p>\n<p>The live webcast presentation will be available\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xt8d5UjChZtPT6w3TL-GenmubFZrZWAyv-cJgdqh-H9SoJ6DR29AsJYvt_4CKn3MjuaC2IGVs6qhFftCkDmH3izrJ_GG6f2HcHnXnOmPHcU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> or on the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JVk34LhQ9Yln5ZFBUdmkzapwXQ215ey5Rh9lKNPK1W7YaahHo5xRH94rzGbnJuuLY51UQxVRAHvcte0ctDaw8g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.arvinas.com<\/a> under <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0jrqms3eBTM4tL2XHKSquWz8IjDRl2nQ2vlyi9czwImnI8kKkXjL-R6e2dgflBvxIfARJQURkYixQdEpyG-pUBEMAFxHjhoggdJdmR_2Tek7H267_LFvgB__T6HuxgFy\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Events + Presentations<\/a>. To access the event via dial-in, please dial (844) 467-7654 (domestic) or (602) 563-8497 (international) and refer to conference ID 9681734. A replay of the webcast will be archived on the Arvinas website following the presentation.<\/p>\n<p>\n        <strong>About\u00a0Arvinas<\/strong><br \/>\n        <br \/>Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC\u00ae Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC\u00ae targeted protein degraders, that are designed to harness the body\u2019s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC\u00ae protein degraders against validated and \u201cundruggable\u201d targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+\/HER2- breast cancer. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JVk34LhQ9Yln5ZFBUdmkzYAsUqXeQcrF2OBT-Xs4iLBAW_wepi_BJQQ226tAJf6U7RbNMSEBglCMgqMCDJ_PnA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.arvinas.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>Contacts for Arvinas<\/strong><br \/>\n        \n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Will O\u2019Connor, Stern Investor Relations <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mdMfO_jm5ccA67Wi98nHal81hrRX56aeV_QP8ZZrDqVEBa1QhHclpX8V1fl3vvmzHwa4hUbRoY6lSGNZMzmXPA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@arvinas.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Kirsten Owens, Arvinas Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EW2TPmAnITr6IIqFiqqi50LOeKlRReUDfdYdibQk7qKWcl8dMeXkBGEUawN1zTFodC08wRxBEqIBRZmVqcNI2rI3gzHMGHB7a6yOd1yuEr0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">kirsten.owens@arvinas.com<\/a>\u00a0<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0ae51430-3625-440d-bf30-6e5bd65e84eb\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET \u2013 NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that\u00a0it will host a live webcast presentation on Monday, December 14, 2020 at 8:00 a.m. ET to provide clinical program updates for its PROTAC\u00ae protein degraders ARV-471 and ARV-110. The presentation will include updates from the Phase 1 dose escalation studies of ARV-471 in patients with locally advanced or metastatic ER positive \/ HER2 negative breast cancer and ARV-110 in men with metastatic castrate-resistant prostate cancer. The event will also include an overview of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398451","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET \u2013 NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that\u00a0it will host a live webcast presentation on Monday, December 14, 2020 at 8:00 a.m. ET to provide clinical program updates for its PROTAC\u00ae protein degraders ARV-471 and ARV-110. The presentation will include updates from the Phase 1 dose escalation studies of ARV-471 in patients with locally advanced or metastatic ER positive \/ HER2 negative breast cancer and ARV-110 in men with metastatic castrate-resistant prostate cancer. The event will also include an overview of &hellip; Continue reading &quot;Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-11T21:18:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs\",\"datePublished\":\"2020-12-11T21:18:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/\"},\"wordCount\":344,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/\",\"name\":\"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=\",\"datePublished\":\"2020-12-11T21:18:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/","og_locale":"en_US","og_type":"article","og_title":"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs - Market Newsdesk","og_description":"\u2013 Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET \u2013 NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that\u00a0it will host a live webcast presentation on Monday, December 14, 2020 at 8:00 a.m. ET to provide clinical program updates for its PROTAC\u00ae protein degraders ARV-471 and ARV-110. The presentation will include updates from the Phase 1 dose escalation studies of ARV-471 in patients with locally advanced or metastatic ER positive \/ HER2 negative breast cancer and ARV-110 in men with metastatic castrate-resistant prostate cancer. The event will also include an overview of &hellip; Continue reading \"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-11T21:18:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs","datePublished":"2020-12-11T21:18:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/"},"wordCount":344,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/","name":"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=","datePublished":"2020-12-11T21:18:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTA4MCMzODY4Mjc4IzIxMjIwNzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac-protein-degrader-development-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC\u00ae Protein Degrader Development Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398451"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398451\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}